Abstract | OBJECTIVE: SUBJECTS AND METHODS: RESULTS: Compared with normal controls, phenacetin apparent clearance decreased by 47.0% (p < 0.05) and 78.7% (p < 0.01) in patients with chronic hepatitis B and cirrhosis, respectively. The recovery of phenacetin O-de-ethylated metabolites decreased by 24.6 and 72.4% (p < 0.01). 46 of 52 HCC patients (88.4%) had an abnormal phenacetin test before TACE, where the ratio of plasma total acetaminophen to phenacetin was below the lower limit of the normal control range. The ratio was less than 50% of normal controls in 6 HCC patients who had a deterioration in liver function from Child-Pugh class A to Child-Pugh class B after TACE. CONCLUSION:
|
Authors | Z Q Qu, X D Li, H L Liu, P He, X Zhang, M C Wu |
Journal | International journal of clinical pharmacology and therapeutics
(Int J Clin Pharmacol Ther)
Vol. 45
Issue 1
Pg. 55-62
(Jan 2007)
ISSN: 0946-1965 [Print] Germany |
PMID | 17256451
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Acetaminophen
- CYP1A2 protein, human
- Cytochrome P-450 CYP1A2
- Phenacetin
|
Topics |
- Acetaminophen
(pharmacokinetics)
- Area Under Curve
- Biotransformation
- Carcinoma, Hepatocellular
(etiology, metabolism, therapy)
- Chemoembolization, Therapeutic
- Cytochrome P-450 CYP1A2
(metabolism)
- Female
- Half-Life
- Hepatitis B, Chronic
(complications, metabolism)
- Humans
- Liver
(enzymology)
- Liver Cirrhosis
(diagnosis, etiology, metabolism)
- Liver Function Tests
(methods)
- Liver Neoplasms
(etiology, metabolism, therapy)
- Male
- Metabolic Clearance Rate
- Middle Aged
- Phenacetin
(pharmacokinetics)
- Predictive Value of Tests
- Severity of Illness Index
- Treatment Outcome
|